Pharma ad PR teams face active FDA enforcement over how broadcast ads present safety information. Novo Nordisk received two FDA untitled letters in February 2026, one for its Wegovy pill TV ad and one for an Ozempic video. The Wegovy letter, dated February 5, cited misleading benefit claims and a failure to present the major statement in audio and on-screen text at the same time. Check every direct-to-consumer script for both before it airs.
Last updated: October 24, 2026. This article is communications guidance, not legal advice. Regulatory counsel should review any drug advertising claim.
In this guide
- What is the dual-modality requirement for drug ads?
- What did FDA say in the Wegovy pill letter?
- What about the Ozempic letter?
- Were other drugmakers cited in 2026?
- How should a company respond publicly to an untitled letter?
- What should PR teams check before a DTC ad airs?
- How does FDA enforcement interact with FTC jurisdiction?
- What regulatory change is next for DTC advertising?
- Frequently asked questions
What is the dual-modality requirement for drug ads?
Dual modality means a broadcast drug ad must present its major statement of risks using audio and on-screen text at the same time, so the spoken and written words match. FDA's rule on presenting the major statement in a clear, conspicuous and neutral manner was finalized in 2023, and the 2026 letters show the agency enforcing it against current campaigns.
In practice, text that appears on screen while the voiceover says something different does not satisfy the requirement, and neither does text that shows up separately from the spoken statement.
What did FDA say in the Wegovy pill letter?
FDA's Office of Prescription Drug Promotion told Novo Nordisk in a letter dated February 5, 2026 that its Wegovy pill TV ad misbrands the drug. The published letter raises three concerns.
- The phrases "live lighter" and "a way forward" misleadingly imply additional weight loss compared with other approved GLP-1 treatments, when that has not been demonstrated.
- The ad implies benefits beyond weight loss, such as emotional relief, reduced psychological burden, hope or direction for patients' lives, which positions the drug as a solution to broader life challenges.
- The major statement includes on-screen text that does not match the audio, so the ad fails to present it concurrently in audio and text.
FDA asked Novo Nordisk for a written response within 15 working days. A Novo Nordisk spokesperson said the company takes regulatory feedback seriously and was responding to address concerns about the ad's presentation, according to CNBC's report.
What about the Ozempic letter?
A second untitled letter followed on February 26, 2026, over an Ozempic video built around the line "There's Only One Ozempic." Reports describe regulators objecting to comedic elements that implied competing drugs lacked meaningful benefits. The sequence matters for PR: two letters in three weeks about two different campaigns from the same company turned a single regulatory matter into a pattern that reporters could cover.
Were other drugmakers cited in 2026?
Yes. Law firm summaries of FDA's 2026 enforcement describe an untitled letter on argenx's Vyvgart Hytrulo TV ad, where the agency alleged that attention-grabbing visuals shown during the major statement interfered with viewers' understanding. eMarketer also reported an FDA letter to Johnson & Johnson calling its Tremfya TV ad false or misleading, citing a "1 out of 2 patients" remission claim and the phrase "100% visible healing." The pattern across letters is consistent: benefit claims that outrun the approved labeling, and risk statements viewers cannot absorb.
How should a company respond publicly to an untitled letter?
A company should confirm receipt, say it is reviewing the specific concerns, reaffirm its commitment to compliant advertising, and avoid disputing FDA's findings publicly before its written response is complete. Novo Nordisk's statements followed that structure. A defensive tone can complicate the regulatory response and invite a longer news cycle.
Coordinate every public statement with regulatory counsel, and make sure anything said about the ad matches what the formal response will say.
What should PR teams check before a DTC ad airs?
- Confirm the major statement appears as on-screen text at the same time it is spoken, word for word.
- Check that visuals during the major statement do not compete with it, since FDA has cited attention-grabbing imagery as interfering with comprehension.
- Review copy for emotional or lifestyle language that implies a benefit beyond the approved indication. "A way forward" read as motivational copy to a marketing team and as an unsupported claim to FDA.
- Test comparative or "only" claims against the prescribing information, since FDA objected where superiority was implied without data.
- Keep a dated review record for each script and revision.
How does FDA enforcement interact with FTC jurisdiction?
FDA regulates prescription drug promotion, while the FTC has general authority over deceptive advertising, so the same claim can be read by two audiences. A statement that fixes the dual-modality problem but keeps a broad lifestyle claim can still draw separate scrutiny, so draft the response to hold up under both standards.
What regulatory change is next for DTC advertising?
FDA has said it intends to pursue rulemaking on the "adequate provision" approach, which lets broadcast ads point to a website or phone number for full risk information. If a final rule narrows that approach, 30 and 60 second spots would carry more risk disclosure, which would push brands toward longer formats or unbranded help-seeking ads. Timing is not confirmed, so check FDA's regulatory agenda before building a plan around a date.
Frequently asked questions
What is FDA's dual-modality rule?
Broadcast drug ads must present the major statement of risks using audio and on-screen text at the same time, with the spoken and written content matching.
How many untitled letters did Novo Nordisk get in February 2026?
Two: one dated February 5 on its Wegovy pill TV ad and one on February 26 on an Ozempic video.
What did FDA object to in the Wegovy pill ad?
The phrases "live lighter" and "a way forward," which it said misleadingly implied additional weight loss and benefits beyond weight loss, and on-screen text that did not match the audio.
How should a company respond to an FDA untitled letter?
Confirm receipt, commit to reviewing the concerns, reaffirm compliance, and avoid public disputes before the written response is filed.
Related Reading
For organizations managing a regulatory letter publicly, see how much crisis PR costs and how to choose a firm, and for brands managing search visibility after a regulatory matter, see online reputation repair: what can be removed. For the practice behind this work, see 5W's healthcare PR practice.
